Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London.
Watch video →What's hot!
View all perspectives
What's Hot
RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk
Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London
Watch video →
Combination Biologics in PsA: MRI Findings from AFFINITY
Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.
Watch video →
Day 4 Recap: EULAR 2026
Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.
Watch video →
EULAR 2026 Recommendations: Immunization
Dr. Jiha Lee reporting from EULAR 2026 in London.
Watch video →
Making Methotrexate More Effective
Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London
Watch video →
Are we failing in the treatment of RA-ILD?
Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.
Watch video →
How Many CAR-Ts Do We Need to Test Drive?
Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.
Watch video →
Day 3 Recap: EULAR 2026
Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288
Watch video →
New axSpA Criteria: Who gets left out?
Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.
Watch video →
PsA Potpourri: Probiotics & Head-to-Head Data
Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.
Watch video →
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read more →
BMI Outranks Treatment in PsA Outcomes?
Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.
Watch video →
BE BOLD: Going Where No PsA Trial Has Gone Before
Dr. Aurelie Najm discusses abstract LB0001 presented at the 2026 EULAR Congress in London
Watch video →
New biomarkers in RA: Who to treat, Who to watch, Who to taper?
Here is my summary of what EULAR 2026 is presenting to us in the field of biomarker-driven personalized care in RA.
Read more →
Debate: Combination Therapies for Inflammatory Arthritis?
Dr. Jonathan Kay reports on the debate, "Combination of targeted therapies in inflammatory arthritis - is the time now?", from EULAR 2026.
Watch video →
What Happens when CAR-T Fails Managing Disease Recurrence
Dr. Alfred Kim discusses abstracts OP0076 and OP0333 presented in London at the EULAR 2026 Congress.
Watch video →
Bella Mehta bella_mehta
6 days 7 hours ago
Emapalumab in MAS secondary to stills disease
39 pts, median age 12, 2 pooled prospective, open label, single arm studies.
Endpoint complete resolution at week 8-. Around 60% and partial resolution nearly 100%
67% had concomitant anakinra
@RheumNow ##EULAR2026 #EULARBest https://t.co/sGm43C3LfH
Aurelie Najm AurelieRheumo
6 days 8 hours ago
Lung US for RA-ILD screening
Comparison with diagnostic scores
147 RA pts (68 ILD on HRCT)
Asymptomatic cohort
Sens 95.4% Spe 77.7%
Risk scores alone performed poorly.
Combining US + risk scores boosted sensitivity to 100% → promising low-cost screening tool alongside HRCT. https://t.co/7C4zClaxry
Aurelie Najm AurelieRheumo
6 days 8 hours ago
Can AI read 20 years of RA X-rays?
And how much faster/better than us?
20 years ESPOIR cohort 7500+ joints
RADAR algorithm
94–95% accuracy compared with expert readers
99% spe 93% sens
#OP0344 #EULAR2026 @RheumNow https://t.co/8hFHCY4SaY
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Dr. John Cush RheumNow
6 days 8 hours ago
Diet as a DMARD? The Evidence Is Still Hard to Swallow
Dietary interventions are rarely taken as seriously as pharmacological therapies in rheumatology. Yet patients ask about them constantly, and an increasing number of studies suggest that nutrition may influence disease https://t.co/BLrr3CNZMg
At EULAR 2026, Dr Nikolaos Kougkas presented data from a unique real-world cohort built within joint dermatology–rheumatology university centers, following 394 patients with psoriasis on bDMARDs for up to 17 years. We sat down with Dr Kougkas to unpack the methodology, challenge the results, and draw out the clinical implications for everyday practice.
Aurelie Najm AurelieRheumo
6 days 8 hours ago
Can AI spot RA inflammation from a thermal hand scan?
Cohort 100 RA pts
AI model analysing thermal images detected US PD+ wrist inflammation AUC 0.87
Main features wrist temperature & heat-pattern
With all due validation could this be the next mass screening tool for RA? https://t.co/2AzXj5yQJI
Aurelie Najm AurelieRheumo
6 days 8 hours ago
No big surprise here, deucravacitinib does as well without MTX
Pooled analysis of 52wk data of POETYK PSA
Same ACR20/50/70 and MDA response profiles also similar safety profiles
#POS0288 #EULAR2026 @RheumNow https://t.co/XqLfZstRuS
The approach to the treatment of peripheral SpA has been the same for a long time. The guidelines recommend starting with NSAIDs, escalate to conventional synthetic DMARDs, typically sulfasalazine or methotrexate and reserve biologics for patients who fail those. According to a new phase 3 trial presented at EULAR 2026, there may be a different way to approach this.
Aurelie Najm AurelieRheumo
6 days 9 hours ago
A biomarker for CV disease in RA?
Anti-CXCR3 antibodies asso w/ atherosclerosis
Confirmed in a validation cohort
Adding Ab profile to the mSCORE increases
AUC from 0.6 to 0.9
Sens from 30 to 69%
How does it compare with other ways of detecting atherosclerosis?
#POS0899 https://t.co/O7bsLrVyzo
Janet Pope Janetbirdope
6 days 9 hours ago
How to treat #RA-#ILD
Similar to #IPF
Occurs older men esp
Smoking risk
Vaccines
Etc
Philippe Dieude
#HOT #EULAR2026 @RheumNow https://t.co/F4h9daSLhF
Nelly ZIADE 🍀 Nellziade
6 days 9 hours ago
Which b/tsDMARDs are effective in #axSpA? Stratified by extramusculoskeletal manifestations
Check out the latest update of the treatment heatmap 🔥
By Astrid van Tubergen
At axial and peripheral SpA at a crossroads session
#EULAR2026
@RheumNow https://t.co/uTxEJqbDBm
